Treatment optimization in early triple negative breast cancer

References

• Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118:5463–5472. doi: 10.1002/cncr.27581
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–172. doi: 10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• de Melo Gagliato, De Melo Gaglaito J, Curigliano G, et al. Tumour infiltrating lymphocytes in breast cancer and implications in clinical practice. Biochim Biophys Acta Rev Cancer. 2017;1868(2):527–537. doi: 10.1016/j.bbcan.2017.10.003
   PubMed Web of Science ®Google Scholar
• Steenbruggen TG, van Werkhoven E, van Ramshorst MS, et al. Adjuvant chemotherapy in small node-negative triple-negative breast cancer. Eur J Cancer. 2020;135:66–74. doi: 10.1016/j.ejca.2020.04.033
   PubMed Web of Science ®Google Scholar
• Lan T, Lu Y, Luo H, et al. The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis. J Cancer. 2020;12:10–17. doi: 10.7150/jca.52540
   Web of Science ®Google Scholar
• Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32:2142–2150. doi: 10.1200/JCO.2013.53.1608
   PubMed Web of Science ®Google Scholar
• Gray R, Bradley R, Braybrooke J, et al. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440–1452. doi: 10.1016/S0140-6736(18)33137-4
   PubMed Web of Science ®Google Scholar
• Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35:2647–2655. doi: 10.1200/JCO.2016.71.4147
   PubMed Web of Science ®Google Scholar
• Nitz U, Gluz O, Clemens, et al. West German study PlanB trial: adjuvant four cycles of Epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019;37:799–808. doi: 10.1200/JCO.18.00028
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019;30:1941–1949. doi: 10.1093/annonc/mdz395
   PubMed Web of Science ®Google Scholar
• de Jong VMT, Wang Y, Ter Hoeve ND, et al. Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)Adjuvant systemic therapy. J Clin Oncol. 2022;40:2361–2374. doi: 10.1200/JCO.21.01536
   PubMed Web of Science ®Google Scholar
• Yau C, van der Noordaa M, Wei J, et al. Abstract GS5-01: residual cancer burden after neoadjuvant therapy and long-term survivaloutcomes in breast cancer: a multi-center pooled analysis. In: General session abstracts. American Association for Cancer Research. Cancer Research; 2020. p. GS5-01-GS5–01. doi: 10.1158/1538-7445.SABCS19-GS5-01
   Google Scholar
• Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747–756. doi: 10.1016/S1470-2045(14)70160-3
   PubMed Web of Science ®Google Scholar
• Lei B, Ping Y, Jiahuai W, et al. Survival benefit of platinum-based regimen in early-stage triple negative breast cancer: a meta-analysis of randomized controlled trials. NPJ Breast Cancer. 2021;21:7. doi: 10.1038/s41523-021-00367-w
   Google Scholar
• Gupta S. Addition of platinum to neoadjuvant chemotherapy in patients with triple negative breast cancer: a phase III randomized trial. Presented At SABCS 2022.
   Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast CancerAn analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684. doi: 10.1001/jamaoncol.2019.6650
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with Pembrolizumab in early triple negative breast cancer. NEJM. 2022;386:556–567. doi: 10.1056/NEJMoa2112651
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. NEJM. 2020;382(9):810–821. doi: 10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30:1279–1288. doi: 10.1093/annonc/mdz158
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–1100. doi: 10.1016/S0140-6736(20)31953-X
   PubMed Web of Science ®Google Scholar
• Douglas JD, Loi S. Immunotherapy in early‑stage triple‑negative breast cancer: where are we Now and where are we headed? Curr Treat Options Oncol. 2023;24:1004–1020. doi: 10.1007/s11864-023-01087-y
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33(5):534–543. doi: 10.1016/j.annonc.2022.02.004
   PubMed Web of Science ®Google Scholar
• Sharma P, Kimler BF, O’Dea A, et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res. 2021;27:975–982. doi: 10.1158/1078-0432.CCR-20-3646
   PubMed Web of Science ®Google Scholar
• Abuhadra N, Stecklein S, Sharma P, et al. Early-stage triple-negative breast cancer: time to optimize personalized strategies. Oncology. 2022;27(1):30–39. doi: 10.1093/oncolo/oyab003
   Google Scholar
• Gluz O, Nitz U, Kolberg-Liedtke C, et al. De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial. Clin Cancer Res. 2022;28:4995–5003. doi: 10.1158/1078-0432.CCR-22-0482
   PubMed Web of Science ®Google Scholar
• Abuhadra N, Sun R, Litton JK, et al. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC). JCO. 2020;38(15_suppl):583–583. doi: 10.1200/JCO.2020.38.15_suppl.583
   Web of Science ®Google Scholar
• Kok M, Nederlof I, Isaeva OI, et al. Nivolumab and ipilimumab in early-stage TNBC with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial. Presented at ESMO; 2022.
   Google Scholar
• Karn T, Denkert C, Weber KE, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;9:1216–1222. doi: 10.1016/j.annonc.2020.05.015
   Google Scholar
• Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, et al. Tumor-specific Major Histocompatibility-II expression Predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer. Clin Cancer Res. 2021;27:5299–5306. doi: 10.1158/1078-0432.CCR-21-0607
   PubMed Web of Science ®Google Scholar
• Stecklein SR, Yoder R, Joshua M, et al. Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): biomarker analysis of the NeoPACT trial. Presented at ASCO, Chicago; 2023.
   Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New Engl J Med. 2017;376:2147–2159. doi: 10.1056/NEJMoa1612645
   PubMed Web of Science ®Google Scholar
• Mayer IA, Zhao F, Arteaga CL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOGACRIN EA 1131. J Clin Oncol. 2021;39:2539–2551. doi: 10.1200/JCO.21.00976
   PubMed Web of Science ®Google Scholar
• Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after standard neo-/Adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01. J Clin Oncol. 2020;38:203–213. doi: 10.1200/JCO.19.00904
   PubMed Web of Science ®Google Scholar
• Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250–1268. doi: 10.1016/j.annonc.2022.09.159
   PubMed Web of Science ®Google Scholar
• Domchek S, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–1164. doi: 10.1016/S1470-2045(20)30324-7
   PubMed Web of Science ®Google Scholar
• Shah AN, Flaum L, Helenowski I, et al. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8(1):e000173. doi: 10.1136/jitc-2019-000173
   PubMed Web of Science ®Google Scholar
• Trapani D, Ferraro E, Giugliano F, et al. Postneoadjuvant treatment for triple-negative breast cancer. Curr Opin Oncol. 2022;34:623–634. doi: 10.1097/CCO.0000000000000893
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133. doi: 10.1126/scitranslmed.aab0021
   PubMed Web of Science ®Google Scholar
• Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–239. doi: 10.1016/j.annonc.2020.11.007
   PubMed Web of Science ®Google Scholar
• Turner NC, Swift C, Jenkin B, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2023;34(2):200–211. doi: 10.1016/j.annonc.2022.11.005
   PubMed Web of Science ®Google Scholar
• Gonçalves A, Bertucci A, Bertucci F. PARP inhibitors in the treatment of early breast cancer: the step beyond? Cancers (Basel). 2020;12:1378. doi: 10.3390/cancers12061378
   PubMedGoogle Scholar
• Litton J, Beck JT, Jones JM, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study. Oncology. 2023;28(10):845–855. ahead of print. doi: 10.1093/oncolo/oyad139
   Google Scholar